# MOTS-c: How It Compares to Other Mitochondrial Peptides

**By TelosRX Editorial Team** · 2026-09-21

**MOTS-c belongs to a small but growing category of mitochondrial-derived peptides. Comparing it honestly with other cellular-energy research compounds means separating mechanism from marketing, since telos rx does not currently offer MOTS-c for compounding.**

What to know

MOTS-c, humanin, and NAD+ precursor compounds all touch cellular energy metabolism, but they work through different biological mechanisms and sit at different points in research and regulatory development. telos rx does not currently offer MOTS-c for compounding while it remains under internal review. This comparison covers mechanism categories only, without fabricated efficacy claims for any of these compounds.

## Why mitochondrial-derived peptides get grouped together

Mitochondrial-derived peptides are a category defined by origin rather than function alone. They are encoded within mitochondrial DNA rather than nuclear DNA, which sets them apart from most other peptides researchers study. MOTS-c and humanin are the two most frequently discussed members of this category.

Grouping compounds by where they come from is useful for researchers, but it can blur real differences in what each peptide actually appears to do. MOTS-c has drawn interest specifically for its possible connection to metabolic regulation and how cells respond to stress, while humanin has been studied more in the context of cellular survival signaling. Treating them as interchangeable would be a mistake.

You can review the current published literature on MOTS-c specifically through the [NIH's PMC database of MOTS-c studies](https://www.ncbi.nlm.nih.gov/pmc/?term=MOTS-c). It is a useful way to see how the research on this particular compound has developed relative to related peptides.

## Where telos rx stands on MOTS-c today

telos rx does not currently offer MOTS-c for compounding. telos rx is reviewing the peptide for its program and has not added it to the current lineup. A 2026 Pharmacy Compounding Advisory Committee (PCAC) review issued non-binding recommendations regarding several research peptides. A recommendation is advice to regulators, not a regulatory approval, and it does not clear a peptide for routine compounding on its own.

You can read more detail about [telos rx's current status on MOTS-c](https://www.telosrx.com/pages/mots-c) directly on its informational page. This comparison article exists to help you understand the category MOTS-c belongs to, not to suggest it is available here.

**Key takeaway:** MOTS-c, humanin, and NAD+ precursors all relate to cellular energy but work through distinct mechanisms, and none of these comparisons implies MOTS-c is available for compounding today.

## MOTS-c versus humanin

MOTS-c and humanin are both mitochondrial-derived peptides, but they have been studied for different aspects of cellular biology. MOTS-c research has focused more on metabolic regulation and how cells adapt to stress on an energy level, while humanin research has centered more on cellular survival and protective signaling pathways.

Both peptides originate from mitochondrial DNA, so they sometimes appear in the same research discussions or review articles. That shared origin does not mean they act the same way in the body, though. Treating them as functionally equivalent oversimplifies a body of research that is still developing for both compounds.

Regulatory status can also differ between mitochondrial-derived peptides over time, even when they are frequently mentioned together, so a source's willingness to offer one does not tell you anything about the other.

## MOTS-c versus NAD+ precursor compounds

NAD+ precursors, including compounds studied for supporting NAD+ levels in cells, represent a different approach to cellular energy support than MOTS-c. NAD+ precursors do not act as a signaling peptide the way MOTS-c does. Instead, they work by supplying raw material the body uses to maintain NAD+, a coenzyme central to how mitochondria generate usable energy.

Both categories touch the broader subject of mitochondrial function, but the mechanism is genuinely different: one is peptide-based signaling, and the other is substrate support for an existing metabolic pathway. Neither should be assumed to produce the same practical effect as the other, since the available research on each follows a different track.

telos rx currently offers [NAD+ nasal spray](https://www.telosrx.com/pages/nad-nasal-spray), which falls into the NAD+ precursor support category rather than the mitochondrial-derived peptide category that MOTS-c belongs to. It is a genuinely different approach, not a like-for-like substitute.

## How research maturity differs across this category

Not every mitochondrial or cellular-energy compound sits at the same stage of research and regulatory clarity. Some substances in this broader space have a longer history of study and more established regulatory pathways, while others, including MOTS-c, remain earlier in that process.

This difference in maturity matters practically. A compound with a longer research and regulatory history is more likely to have settled sourcing standards and clearer compounding guidance. A newer compound like MOTS-c is more likely to sit in the kind of gray zone that keeps a cautious pharmacy from adding it to a program. The FDA's own overview of how it evaluates substances for compounding, at its [compounding questions and answers page](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers), explains the general framework behind that process.

When comparing options in this space, it is worth asking not just what a compound is studied for, but how far along its regulatory picture actually is. Those two questions can have very different answers even for peptides that get discussed in the same sentence.

## What "comparable mechanism" does and does not mean

Describing two compounds as working in the same category, such as cellular energy metabolism, is not a claim that they produce comparable outcomes. Mechanism category is a starting point for understanding a compound, not a prediction of its effects.

It is also worth being cautious of any source that implies one compound is simply a substitute for another because they touch a similar biological system. Peptide signaling and metabolic substrate support are different tools. That remains true even when both get filed under the same broad umbrella of mitochondrial health.

The most honest way to compare MOTS-c with other cellular-energy compounds is by mechanism category, described plainly. That approach avoids implying interchangeable effects or borrowing research findings from one compound to describe another entirely.

## MOTS-c versus growth-hormone-related peptides

It is also worth distinguishing MOTS-c from a separate category entirely: growth-hormone-related peptides such as sermorelin. These compounds work by stimulating the body's own growth hormone release through the pituitary gland, a mechanism unrelated to the mitochondrial signaling pathways associated with MOTS-c.

The two categories sometimes get lumped together in casual peptide discussions simply because both are framed around vitality or wellness goals. That framing is loose and not especially useful for understanding what either compound actually does at a mechanistic level. Growth-hormone-related peptides and mitochondrial-derived peptides belong to different families with different biological targets entirely.

telos rx currently offers sermorelin for patients interested in that specific mechanism. It should not be confused with, or presented as related to, MOTS-c beyond both existing within the broader peptide research landscape.

## Why category comparisons should stay descriptive, not promotional

A comparison article like this one can easily slide into implying that one available option is "just as good" as an unavailable one. That is not the intent here. MOTS-c and NAD+ precursors, for example, are different tools with different research bases, and neither should be marketed as a replacement for the other.

The goal of a mechanism-based comparison is to help you understand the landscape accurately, not to nudge you toward whatever happens to be available today. If a source frames an available product as functionally identical to an unavailable one purely to close a sale, that is worth treating with real skepticism.

telos rx's own position is straightforward. MOTS-c is not part of the program today. NAD+ nasal spray is available and addresses a related but distinct area of cellular energy. Neither statement is meant to blur into the other.

## Which is right for you

Your interest in MOTS-c may come from a broader curiosity about mitochondrial and cellular energy support. If so, telos rx currently offers [NAD+ nasal spray](https://www.telosrx.com/pages/nad-nasal-spray) as a real, available option in that general space. It works through a different mechanism than MOTS-c, so it should be evaluated on its own terms rather than as a direct swap.

telos rx also currently offers [BPC-157](https://www.telosrx.com/pages/bpc-157) for tissue-support goals, [sermorelin](https://www.telosrx.com/pages/sermorelin) for growth-hormone-related goals, and [PT-141](https://www.telosrx.com/pages/pt-141) for a separate use case. A licensed provider can help you think through which available option, if any, actually fits what you are trying to achieve.

[Start your NAD+ visit →](https://start.telosrx.com/start-online-visit/peptides)

## Frequently Asked Questions

### Is MOTS-c the same as humanin?

No. Both are mitochondrial-derived peptides, but they have been studied for different aspects of cellular biology, with MOTS-c linked more to metabolic regulation and humanin more to cellular survival signaling.

### How does MOTS-c compare to NAD+ precursor compounds?

They work through different mechanisms. MOTS-c is studied as a signaling peptide, while NAD+ precursors supply material the body uses to maintain NAD+, a coenzyme involved in mitochondrial energy production.

### Does telos rx offer MOTS-c?

No. telos rx does not currently offer MOTS-c for compounding because the peptide is still under internal review and has not been added to the program.

### Is NAD+ nasal spray a substitute for MOTS-c?

No. It addresses a related area of cellular energy metabolism through a different mechanism and should not be treated as equivalent to MOTS-c.

### Why do mitochondrial-derived peptides get discussed together so often?

They share a common origin within mitochondrial DNA, which groups them in research discussions even though individual compounds like MOTS-c and humanin appear to function differently.

### Where can I check telos rx's current status on MOTS-c?

telos rx maintains a dedicated informational page describing its current status on MOTS-c, and that page is the most reliable place to check for updates.

_TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Questions about telos rx's current peptide program? [See available peptides](https://telosrx.com/pages/peptides) or start your evaluation at [TelosRX](https://telosrx.com).

**Tags:** mitochondrial health, mots-c, peptides

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/mots-c-how-it-compares-to-other-mitochondrial-peptides)